他莫昔芬药物遗传学与代谢:前瞻性CYPTAM研究结果
前瞻性CYPTAM研究纳入667例接受辅助他莫昔芬治疗的早期乳腺癌患者,评估内皮昔芬浓度和CYP2D6基因型与无复发生存期的关联。中位治疗0.37年后入组,未发现内皮昔芬浓度(校正HR 0.991,95%CI 0.946-1.038,P=0.691)或CYP2D6基因型(校正HR 0.929,95%CI 0.525-1.642,P=0.799)与RFSt相关。
要点
- 内皮昔芬浓度与无复发生存期无关联(校正HR 0.991,95%CI 0.946-1.038)。
- 将内皮昔芬浓度按四分位或5.9 ng/mL阈值分组,结果均无改变。
- CYP2D6基因型与无复发生存期无关联(校正HR 0.929,95%CI 0.525-1.642)。
核心结论
- 前瞻性临床研究显示,在接受辅助他莫昔芬治疗的早期乳腺癌患者中,内皮昔芬浓度或CYP2D6基因型与临床结局无关联。
研究设计与样本
- 前瞻性CYPTAM研究(荷兰国家试验注册号NTR1509),2008年2月至2010年12月纳入接受辅助他莫昔芬治疗的乳腺癌患者。
- 患者可在开始他莫昔芬治疗后最长12个月内入组,共667例绝经前和绝经后患者入组。
- 入组前他莫昔芬治疗中位时间为0.37年(范围0.23至0.6年)。
- 采用Amplichip(Roche Diagnostics,Indianapolis,IN)进行CYP2D6基因分型,高效液相色谱-串联质谱法测定内皮昔芬浓度。
- 内皮昔芬浓度作为连续变量分析,并按四分位数分类及使用5.9 ng/mL阈值,采用Cox回归分析其与无复发生存期(以他莫昔芬停药时间删失,RFSt)的关联。
主要发现
- 内皮昔芬浓度与RFSt无关联(校正风险比0.991;95%CI 0.946至1.038;P=0.691)。
- 将内皮昔芬浓度按四分位数分类或使用5.9 ng/mL作为阈值均未改变上述结果。
- CYP2D6基因型与RFSt无关联(校正风险比0.929;95%CI 0.525至1.642;P=0.799)。
关键数值与推荐
- 内皮昔芬疗效阈值5.9 ng/mL源自回顾性研究,前瞻性研究缺乏确认。
- 内皮昔芬浓度连续变量校正风险比0.991(95%CI 0.946至1.038;P=0.691)。
- CYP2D6基因型校正风险比0.929(95%CI 0.525至1.642;P=0.799)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Tamoxifen is widely prescribed as adjuvant therapy in patients with early-stage breast cancer. It has been postulated that concentrations of endoxifen, the active metabolite of tamoxifen, are a better predictor of tamoxifen efficacy than CYP2D6 genotypes. Although in a retrospective study, an endoxifen threshold of 5.9 ng/mL for efficacy was described, confirmation based on prospective studies is lacking. The objective of the prospective CYPTAM (The Netherlands National Trial Register: NTR1509) study was to associate endoxifen concentrations and CYP2D6 genotypes with clinical outcome in patients with early-stage breast cancer receiving tamoxifen. PATIENTS AND METHODS: From February 2008 to December 2010, patients with breast cancer treated with adjuvant tamoxifen were included. Patients could be enrolled up to a maximum of 12 months after tamoxifen initiation. Blood samples were retrieved for CYP2D6 genotyping and endoxifen measurements by Amplichip (Roche Diagnostics, Indianapolis, IN) and high-performance liquid chromatography-tandem mass spectrometry, respectively. Endoxifen concentrations were analyzed as a continuous variable, classifying patients into quartiles and using an endoxifen threshold of 5.9 ng/mL. Endoxifen concentrations and CYP2D6 genotypes were associated with relapse-free survival (censored at the time of tamoxifen discontinuation; RFSt) by Cox regression analysis. RESULTS: A total of 667 pre- and postmenopausal patients were enrolled and had received tamoxifen for a median time of 0.37 years (range, 0.23 to 0.6 years) before study entry. No association was found between endoxifen concentrations and RFSt (adjusted hazard ratio, 0.991; 95% CI, 0.946 to 1.038; P = .691). Also, neither categorizing endoxifen concentrations into quartiles nor using 5.9 ng/mL as threshold altered these results. In addition, no association was found between CYP2D6 genotype and RFSt (adjusted hazard ratio, 0.929; 95% CI, 0.525 to 1.642; P = .799). CONCLUSION: This prospective clinical study shows no association between endoxifen concentrations or CYP2D6 genotypes and clinical outcome in patients with early-stage breast cancer receiving adjuvant tamoxifen.
引用
- Sanchez-Spitman A, Dezentjé V, Swen J, et al. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study. J Clin Oncol. 2019. PMID: 30676859. doi:10.1200/JCO.18.00307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。